Soligenix Stock Today
| SNGX Stock | USD 2.21 0.06 2.64% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Soligenix is trading at 2.21 as of the 29th of March 2025; that is 2.64 percent decrease since the beginning of the trading day. The stock's open price was 2.27. Soligenix has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 29th of December 2024 and ending today, the 29th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of June 1987 | Category Healthcare | Classification Health Care |
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. Soligenix operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 2.51 M outstanding shares of which 106.42 K shares are at this time shorted by private and institutional investors with about 2.51 trading days to cover. More on Soligenix
Moving together with Soligenix Stock
Moving against Soligenix Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Soligenix Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman, CEO and Pres | Christopher Schaber | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSoligenix can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Soligenix's financial leverage. It provides some insight into what part of Soligenix's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Soligenix (SNGX) is traded on NASDAQ Exchange in USA. It is located in 29 Emmons Drive, Princeton, NJ, United States, 08540 and employs 14 people. Soligenix is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.55 M. Soligenix conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.51 M outstanding shares of which 106.42 K shares are at this time shorted by private and institutional investors with about 2.51 trading days to cover.
Soligenix currently holds about 20.16 M in cash with (8.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47.
Check Soligenix Probability Of Bankruptcy
Ownership AllocationAbout 99.02 % of Soligenix outstanding shares are held by general public with 0.02 (%) owned by insiders and only 0.96 % by institutional holders.
Check Soligenix Ownership Details
Soligenix Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Northern Trust Investments N A | 2024-12-31 | 0.0 | |
| Fmr Inc | 2024-09-30 | 0.0 | |
| Old National Bancorp | 2024-09-30 | 0.0 | |
| Armistice Capital, Llc | 2024-09-30 | 0.0 | |
| Geode Capital Management, Llc | 2024-12-31 | 26.1 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 3.8 K | |
| Ubs Group Ag | 2024-12-31 | 313 | |
| Plante Moran Financial Advisors Lp | 2024-12-31 | 300 | |
| Bank Of America Corp | 2024-12-31 | 20.0 | |
| Jones Financial Companies Lllp | 2024-12-31 | 10.0 | |
| Sbi Securities Co Ltd | 2024-12-31 | 2.0 |
Soligenix Historical Income Statement
Soligenix Stock Against Markets
Soligenix Corporate Management
| Oreola Donini | Chief Scientific Officer and Sr. VP | Profile | |
| Richard Dunning | Ex Officer | Profile | |
| CGMA CPA | CFO VP | Profile | |
| MSc MD | Senior Officer | Profile |
Additional Tools for Soligenix Stock Analysis
When running Soligenix's price analysis, check to measure Soligenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Soligenix is operating at the current time. Most of Soligenix's value examination focuses on studying past and present price action to predict the probability of Soligenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Soligenix's price. Additionally, you may evaluate how the addition of Soligenix to your portfolios can decrease your overall portfolio volatility.